ATE368227T1 - Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können - Google Patents

Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können

Info

Publication number: ATE368227T1
Authority: AT; Austria
Prior art keywords: tgf; agents; screening; compounds; dependent cell
Prior art date: 1999-08-30

Application number

AT00959571T

Other languages

English (en)

Inventor

Merl Hoekstra

Weilin Xie

Brion Murray

Frank Mercurio

Original Assignee

Signal Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-30

Filing date

2000-08-29

Publication date

2007-08-15

2000-08-29 Application filed by Signal Pharm Inc filed Critical Signal Pharm Inc

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE368227T1 publication Critical patent/ATE368227T1/de

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 5
150000001875 compounds Chemical class 0.000 title 1
230000001419 dependent effect Effects 0.000 title 1
238000012216 screening Methods 0.000 title 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 4
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 4
239000003795 chemical substances by application Substances 0.000 abstract 4
230000001404 mediated effect Effects 0.000 abstract 2
230000011664 signaling Effects 0.000 abstract 2
102000007374 Smad Proteins Human genes 0.000 abstract 1
108010007945 Smad Proteins Proteins 0.000 abstract 1
210000000988 bone and bone Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000000921 morphogenic effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000017854 proteolysis Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Hematology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pathology (AREA)
Endocrinology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Food Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT00959571T 1999-08-30 2000-08-29 Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können ATE368227T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/385,918 US7358056B1 (en)	1999-08-30	1999-08-30	Methods for modulating signal transduction mediated by TGF-β and related proteins

Publications (1)

Publication Number	Publication Date
ATE368227T1 true ATE368227T1 (de)	2007-08-15

Family

ID=23523429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00959571T ATE368227T1 (de)	1999-08-30	2000-08-29	Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können

Country Status (8)

Country	Link
US (2)	US7358056B1 (de)
EP (2)	EP1212621B1 (de)
JP (1)	JP2003508755A (de)
AT (1)	ATE368227T1 (de)
AU (1)	AU781152B2 (de)
CA (1)	CA2383514A1 (de)
DE (1)	DE60035697T2 (de)
WO (1)	WO2001016604A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2443842A1 (en) *	2001-04-10	2002-10-24	Children's Medical Center Corporation	Methods of analysis and labeling of protein-protein interactions
ATE420670T1 (de) *	2001-04-25	2009-01-15	Eidgenoess Tech Hochschule	Arzneimittel freisetzende matrizen zur förderung der wundheilung
BR0213100A (pt) *	2001-10-05	2004-11-30	Combinatorx Inc	Combinações para o tratamento de distúrbios imuniinflamatórios
GB0302315D0 (en) *	2003-02-01	2003-03-05	Univ East Anglia	Novel therapeutic target
CA2574777C (en) *	2004-07-23	2015-09-01	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
WO2008153814A2 (en) *	2007-05-29	2008-12-18	President And Fellows Of Harvard College	Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2011088163A1 (en)	2010-01-14	2011-07-21	President And Fellows Of Harvard College	Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
GB201013284D0 (en) *	2010-08-06	2010-09-22	Isogenica Ltd	Scaffold peptides
PT2981822T (pt)	2013-05-06	2020-12-07	Scholar Rock Inc	Composições e métodos para modulação do fator de crescimento
CN103558395B (zh) *	2013-10-28	2015-08-26	深圳市第二人民医院	Smad3基因在检测上尿路上皮癌中的应用
KR101683544B1 (ko) *	2014-12-19	2016-12-08	한양대학교 산학협력단	탈인산화 또는 인산화 효소 활성 검출용 조성물 및 검출 방법
US10961305B2 (en)	2016-12-21	2021-03-30	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AU2020275425B2 (en) *	2019-05-15	2024-06-27	Synthex, Inc.	Selective degradation of proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6001619A (en)	1995-10-04	1999-12-14	Cold Spring Harbor Laboratory	Ubiquitin ligases, and uses related thereto
US6011137A (en) *	1996-04-03	2000-01-04	University Of North Carolina At Chapel Hill	Identification and isolation of novel polypeptides having WW domains and methods of using same
US6103869A (en)	1997-05-20	2000-08-15	Ludwig Institute For Cancer Research	Smad2 phosphorylation and interaction with Smad4
WO1999001765A1 (en)	1997-07-01	1999-01-14	Sloan Kettering Institute For Cancer Research	METHODS OF INHIBITING OR ENHANCING THE TGFβ-SMAD SIGNALING PATHWAY
US6060262A (en)	1997-07-16	2000-05-09	Mitotix, Inc.	Regulation of I Kappa B (IκB) degradation and methods and reagents related thereto
US5976849A (en) *	1998-02-05	1999-11-02	Zeneca Limited	Human E3 ubiquitin protein ligase
AU782355B2 (en)	1999-06-11	2005-07-21	Hsc Research And Development Limited Partnership	Antagonists of BMP and TGFbeta signalling pathways

1999
- 1999-08-30 US US09/385,918 patent/US7358056B1/en not_active Expired - Fee Related
2000
- 2000-08-29 AT AT00959571T patent/ATE368227T1/de not_active IP Right Cessation
- 2000-08-29 AU AU70866/00A patent/AU781152B2/en not_active Ceased
- 2000-08-29 DE DE60035697T patent/DE60035697T2/de not_active Expired - Fee Related
- 2000-08-29 EP EP00959571A patent/EP1212621B1/de not_active Expired - Lifetime
- 2000-08-29 WO PCT/US2000/023729 patent/WO2001016604A1/en active IP Right Grant
- 2000-08-29 JP JP2001520108A patent/JP2003508755A/ja active Pending
- 2000-08-29 CA CA002383514A patent/CA2383514A1/en not_active Abandoned
- 2000-08-29 EP EP07010063A patent/EP1918716A2/de not_active Withdrawn
2002
- 2002-12-02 US US10/307,956 patent/US20030119072A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60035697D1 (de)	2007-09-06
US20030119072A1 (en)	2003-06-26
DE60035697T2 (de)	2008-04-30
WO2001016604A1 (en)	2001-03-08
AU781152B2 (en)	2005-05-12
EP1212621B1 (de)	2007-07-25
CA2383514A1 (en)	2001-03-08
EP1918716A2 (de)	2008-05-07
AU7086600A (en)	2001-03-26
EP1212621A1 (de)	2002-06-12
JP2003508755A (ja)	2003-03-04
US7358056B1 (en)	2008-04-15

Publication	Publication Date	Title
ATE368227T1 (de)	2007-08-15	Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können
DE122009000012I1 (de)	2011-12-01	Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE59611411D1 (de)	2007-02-22	Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
MX9207074A (es)	1993-07-01	Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
DE69427869D1 (de)	2001-09-06	Botulinumtoxine zur behandlung von hyperhydrosis
ATE271058T1 (de)	2004-07-15	Mycophenol bisphosponatverbindungen
ATE337021T1 (de)	2006-09-15	Anordnungen, systeme und verfahren zur behandlung von biologischen flüssigkeiten mit licht
ATE353640T1 (de)	2007-03-15	Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
DE59709515D1 (de)	2003-04-17	Verfahren zur herstellung von wirkstoffhaltigen knochenzementen
AR010062A1 (es)	2000-05-17	Nuevos benzamidaldehidos y su utilizacion
DE69939864D1 (de)	2008-12-18	Ppar-gamma modulatoren
DE60029812D1 (de)	2006-09-14	Diagnose von zellenproliferation sowie screeningverfahren für deren modulatore
DK1113810T3 (da)	2009-04-06	Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
ATE255632T1 (de)	2003-12-15	Immortalisierung bzw. desimmortalisierung von zellen
ATE311853T1 (de)	2005-12-15	Verwendung von krillenzymen zur behandlung von zahnbelag
DE60021381D1 (de)	2005-08-25	Chinonverbindungen zur behandlung von krankheiten
DE69013999D1 (de)	1994-12-15	Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DE69425820D1 (de)	2000-10-12	Verwendung von ferrioxamin-b zur behandlung septischen schocks
YU41998A (sh)	1999-07-28	Tetrahidrobetakarbolinska jedinjenja
DK0871457T3 (da)	2003-07-28	Isolerede stromaceller og fremgangsmåder til anvendelse heraf
DE60112742D1 (de)	2005-09-22	Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE254128T1 (de)	2003-11-15	Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE69939723D1 (de)	2008-11-20	Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
MX9101958A (es)	1992-07-08	Inhibidores de acat de urea de aminosulfonilo
FI921721A7 (fi)	1992-10-17	Menetelmä biologisten aineiden erityisesti nopeutettua, aerobista mikrobiologista hajottamista varten

Legal Events

Date	Code	Title	Description
2008-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties